Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Bioinformatic identification of FGF, p38-MAPK, and calcium signalling pathways associated with carcinoma in situ in the urinary bladder.

Herbsleb M, Christensen OF, Thykjaer T, Wiuf C, Borre M, Orntoft TF, Dyrskjøt L.

BMC Cancer. 2008 Jan 31;8:37. doi: 10.1186/1471-2407-8-37.

2.

Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.

Dyrskjøt L, Kruhøffer M, Thykjaer T, Marcussen N, Jensen JL, Møller K, Ørntoft TF.

Cancer Res. 2004 Jun 1;64(11):4040-8.

3.

Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.

Guo CC, Fine SW, Epstein JI.

Am J Surg Pathol. 2006 Jul;30(7):883-91.

PMID:
16819332
4.

Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study.

Dyrskjøt L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S, Knowles M, Malmström PU, de la Torre M, Wester K, Allory Y, Vordos D, Caillault A, Radvanyi F, Hein AM, Jensen JL, Jensen KM, Marcussen N, Orntoft TF.

Clin Cancer Res. 2007 Jun 15;13(12):3545-51.

5.

Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases.

Hara T, Takahashi M, Gondo T, Nagao K, Ohmi C, Sakano S, Naito K, Matsuyama H.

Int J Urol. 2009 Mar;16(3):293-8. doi: 10.1111/j.1442-2042.2008.02241.x.

7.

Molecular genetics of bladder cancer: an update.

Díaz De Ståhl T, Segersten U, Malmström PU.

Minerva Urol Nefrol. 2008 Dec;60(4):205-16. Review.

PMID:
18923358
8.

Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder.

Takenaka A, Yamada Y, Miyake H, Hara I, Fujisawa M.

Int J Urol. 2008 Apr;15(4):309-13. doi: 10.1111/j.1442-2042.2008.02012.x.

9.

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.

Zieger K, Dyrskjøt L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, Ørntoft TF.

Clin Cancer Res. 2005 Nov 1;11(21):7709-19.

10.

Molecular alterations associated with bladder cancer initiation and progression.

Cordon-Cardo C.

Scand J Urol Nephrol Suppl. 2008 Sep;(218):154-65. doi: 10.1080/03008880802291915. Review.

PMID:
18815930
11.

Improved gene expression signature of testicular carcinoma in situ.

Almstrup K, Leffers H, Lothe RA, Skakkebaek NE, Sonne SB, Nielsen JE, Rajpert-De Meyts E, Skotheim RI.

Int J Androl. 2007 Aug;30(4):292-302; discussion 303.

PMID:
17488342
12.

Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors.

Palou J, Rodríguez-Rubio F, Millán F, Algaba F, Rodríguez-Faba O, Huguet J, Villavicencio H.

Urology. 2009 Jun;73(6):1313-7. doi: 10.1016/j.urology.2008.12.047.

PMID:
19362341
13.

Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion.

Moon A, Yong HY, Song JI, Cukovic D, Salagrama S, Kaplan D, Putt D, Kim H, Dombkowski A, Kim HR.

Mol Cancer Res. 2008 Oct;6(10):1544-53. doi: 10.1158/1541-7786.MCR-08-0189.

14.

[Identification of gene expression patterns in superficial and invasive human bladder cancers].

Zhou L, Shi BT, Wang SX, Luo Y, Yang L, Zhang LL, Wang XY, He DL.

Zhonghua Yi Xue Za Zhi. 2007 Mar 27;87(12):798-801. Chinese.

PMID:
17565857
15.

Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer.

Fauconnet S, Bernardini S, Lascombe I, Boiteux G, Clairotte A, Monnien F, Chabannes E, Bittard H.

Oncol Rep. 2009 Jun;21(6):1495-504.

PMID:
19424629
16.

Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro.

Dyrskjøt L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, Kauppinen S, Ulhøi BP, Kjems J, Borre M, Orntoft TF.

Cancer Res. 2009 Jun 1;69(11):4851-60. doi: 10.1158/0008-5472.CAN-08-4043.

17.

The origins of urothelial carcinoma.

Cheng L, Davidson DD, Maclennan GT, Williamson SR, Zhang S, Koch MO, Montironi R, Lopez-Beltran A.

Expert Rev Anticancer Ther. 2010 Jun;10(6):865-80. doi: 10.1586/era.10.73. Review.

PMID:
20553211
18.

Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling.

Qian Y, Deng J, Xie H, Geng L, Zhou L, Wang Y, Yin S, Feng X, Zheng S.

J Cancer Res Clin Oncol. 2009 Mar;135(3):379-86. doi: 10.1007/s00432-008-0478-z.

PMID:
18825409
19.

Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder.

Cheng J, Huang H, Pak J, Shapiro E, Sun TT, Cordon-Cardo C, Waldman FM, Wu XR.

Cancer Res. 2003 Jan 1;63(1):179-85.

20.

ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients.

Mueller J, von Eggeling F, Driesch D, Schubert J, Melle C, Junker K.

Eur Urol. 2005 Jun;47(6):885-93; discussion 893-4.

PMID:
15925088
Items per page

Supplemental Content

Support Center